BOPA member published in the Journal of Oncology Pharmacy Practice

International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions

Immunotherapy is an evolving therapeutic modality which confers a range of clinical advantages in the treatment of malignant disease. Oncology pharmacists, pharmacy technicians and assistants are key members of the multidisciplinary health care team caring for patients receiving immunotherapy. The International Society of Oncology Pharmacy Practitioners (ISOPP) has developed a position statement to provide guidance to pharmacy professionals working in this field and to promote the role that pharmacy staff have to offer in providing safe and effective treatment with immunotherapy.

Four key recommendations were identified:

1) participation as an integrated, collaborative member of the MHT

1) provision of education and training for patients, students, residents, fellows and other members of the MHT

3) involvement in clinical governance to optimise the use of immune checkpoint inhibitors

4) involvement in research and development in the field of immunotherapy.

 

Read the full article here: https://journals.sagepub.com/doi/10.1177/10781552221090199 

Latest News

By BOPA on 12th May 2022

REGISTRATION NOW OPEN – The 25th Annual BOPA Symposium, 7-9 October, Liverpool

An important date for your diaries: The 25th British Oncology Pharmacy Association (BOPA) Annual Symposium (7th – 9th October). Oncology and haematology are ever-changing landscapes and this year we are looking to…

Read article
By BOPA Committee on 11th May 2022

Vote for the 2023 Symposium Venue: PAID members

The BOPA committee are giving all PAID members of BOPA the opportunity to help inform the choice of venue for the 2023 BOPA symposium. If you wish to take part…

Read article
By BOPA Committee on 11th May 2022

PUBLIC CONSULTATION NOW OPEN ** Draft International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) **

The ADDIKD draft guideline is open for public consultation until midnight (AEST) 31st May 2022.  The BOPA Committee would appreciate your input with this process. The Draft Guideline can be…

Read article
By BOPA Committee on 11th May 2022

UK Oncology Forum

Dear Colleague Unfortunately, the ACP has now had to cancel the Town Hall meeting, scheduled at the forthcoming UK Oncology Forum. The committee apologise for any inconvenience caused. However –…

Read article

25th BOPA Symposium 2022

7th to 9th October 2022 at The ACC Liverpool

REGISTRATION NOW OPEN!
Members: www.bopa.org.uk/2022-members-symposium-link/
Non members: Contact Media1Productions: [email protected]
Please see Key information before for accommodation information.

DRAFT AGENDA
Please click here to view the latest agenda.

CONFERENCE FEES (includes VAT)
Early-bird rate applies up until Monday 22nd August 2022

Everything you need to know